CytRx Corporation, a biopharmaceutical research and development company specialising in oncology, has hired Olivia Ware as Chief Commercial Officer, a new executive management position. She also becomes a member of the firm's senior executive team.
Ware brings more than 20 years of biotechnology and pharmaceutical experience to the US firm, which is based in Los Angeles, including 13 years at Genentech where she was responsible for key aspects of the launches of the oncology drugs Rituxan, Herceptin and Avastin.
'We are very fortunate to have Olivia join the CytRx team. She is a seasoned veteran who has played key roles in the launching of several of the world's largest revenue-producing oncology drugs,' said Steven Kriegsman, Chairman and CEO.
'The creation of this new executive management position reflects our transition to a commercial organisation as we prepare for the results from our pivotal Phase III trial with aldoxorubicin as a treatment for patients with relapsed or refractory soft tissue sarcomas.'
While at Genentech, Ware was a Senior Director of Oncology. Prior to this, she was Head of Herceptin marketing and held a number of other positions in the commercial organisation. Later, she was a Senior Director in the Product Portfolio Management Group.
Since leaving Genentech, Ware has worked as an independent consultant. Prior to Genentech, she worked in healthcare consulting for Baxter Healthcare and was the Western Region General Manager for a large national home healthcare company.
